Naquotinib also inhibits signaling pathways through ERK and Akt, and is active against EGFR mutant cell lines resistant to other EGFR TKIs such as AZD9291 and CO-1686.194,195 In May 2017, Astellas announced the termination of a phase III clinical study (NCT02588261) of naquotinib in NSCLC due to a recommendation from the Independent Data Monitoring Committee (IDMC). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.